Please login to the form below

Not currently logged in
Email:
Password:

Wolters Kluwer drops pharma business

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market.

Nancy McKinstry, CEO and chairman of the executive board of Wolters Kluwer, said: "The planned divestment of the pharma business will focus our health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of health, to deliver enhanced value to our stakeholders."

The company's pharmaceutical business currently includes products such as Source and Adis, with services providing support in development, marketing and distribution. This is made in available through textbooks and journals, electronic drug data, clinical information, and other evidence-based content.

The divestiture is expected to close around the end of the 2011.

27th July 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics